Drug maker AstraZeneca says a new antidepressant drug it hopes will be a big money-earner did not perform as well as expected in a test. AstraZeneca, which is developing the drug, known as TC-5214. in collaboration with U.S.-based Targacept, said Tuesday that the drug did not perform as well as hoped versus a placebo in the first of four tests in Phase III trials.
For more from BostonGlobe.com, sign up or log in below
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Get FREE access as part of your print subscription.
Click to continue reading this article or to log in to BostonGlobe.com.